Vav3-Rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence

Cancer Research

Volumn 72, Issue 12, 2012, Pages 3000-3009

  Lin, Kai Ti ^a   Gong, Jianli ^b   Li, Chien Feng ^d   Jang, Te Hsuan ^a   Chen, Wen Ling ^a   Chen, Huei Jane ^a   Wang, Lu Hai ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Columbia University ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN A1; EPHRIN RECEPTOR A2; GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAC1 PROTEIN; UNCLASSIFIED DRUG; VAV PROTEIN; VAV3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REGULATORY MECHANISM; RISK REDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; EPHRIN-A1; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-VAV; RAC1 GTP-BINDING PROTEIN; RECEPTOR, EPHA2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84862546529     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2502     Document Type: Article

References (43)

1. Movilla N, Bustelo XR. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol 1999;19:7870-85. (Pubitemid 29493450)
2. Trenkle T, McClelland M, Adlkofer K, Welsh J. Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 2000;245:139-49. (Pubitemid 30125373)
3. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, et al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 2000;20:9212-24. (Pubitemid 32246108)
4. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000;20:1461-77. (Pubitemid 30100166)
5. Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, et al. Vav family proteins couple to diverse cell surface receptors. Mol Cell Biol 2000;20:6364-73. (Pubitemid 30650223)
6. Aghazadeh B, Lowry WE, Huang XY, Rosen MK. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 2000;102:625-33.
7. Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, Tybulewicz VL, et al. Vav3 regulates osteoclast function and bone mass. Nat Med 2005;11:284-90. (Pubitemid 40460556)
8. Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, Lopez-Novoa JM, et al. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med 2006;12:841-5. (Pubitemid 44050076)
9. Sindrilaru A, Peters T, Schymeinsky J, Oreshkova T, Wang H, Gompf A, et al. Wound healing defect of Vav3-/-mice due to impaired {beta}2-integrin- dependent macrophage phagocytosis of apoptotic neutrophils. Blood 2009;113:5266-76.
10. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005;24:7859-68. (Pubitemid 41715192)
11. Merlos-Suarez A, Batlle E. Eph-ephrin signalling in adult tissues and cancer. Curr Opin Cell Biol 2008;20:194-200.
12. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10:165-80.
13. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41:275-80.
14. Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003;163:2271-6. (Pubitemid 37466471)
15. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 2003;20:59-68. (Pubitemid 36308137)
16. Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, et al. Kinase-dependent and-independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 2009;174:1492-503.
17. Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol 2006;26:4830-42. (Pubitemid 43955801)
18. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006;20:2315-25. (Pubitemid 44496404)
19. Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 2006;20:1061-72.
20. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010;5:e13500.
21. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 2008;22:597-608. (Pubitemid 351397788)
22. Liu Y, Wu X, Dong Z, Lu S. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells. Int J Oncol 2010;36:623-33.
23. Dong Z, Liu Y, Levin L, Oleksowicz L, Wang J, Lu S. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. Oncol Rep 2011;25:1511-6.
24. Liu Y, Mo JQ, Hu Q, Boivin G, Levin L, Lu S, et al. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res 2008;68:6396-406.
25. Sachdev P, Zeng L, Wang LH. Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes. J Biol Chem 2002;277:17638-48. (Pubitemid 34967567)
26. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-7.
27. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44:91-103. (Pubitemid 30419183)
28. Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem 2008;283:16017-26.
29. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9. (Pubitemid 41124175)
30. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005;19:1884-6. (Pubitemid 41598783)
31. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009;16:9-20.
32. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000;2:62-9.
33. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002;21:7690-9. (Pubitemid 35398815)
34. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008;9:690-701.
35. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004;1705:121-32.
36. Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 2007;67:8089-94. (Pubitemid 47395143)
37. Engers R, Ziegler S, Mueller M, Walter A, Willers R, Gabbert HE. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocr Relat Cancer 2007;14:245-56. (Pubitemid 47242626)
38. Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, et al. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 2004;23:5513-22. (Pubitemid 39044062)
39. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 2002;417:867-71. (Pubitemid 34670335)
40. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008;135:510-23.
41. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 2004;101:7618-23. (Pubitemid 38658078)
42. Kheradmand F, Werner E, Tremble P, Symons M, Werb Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998;280:898-902. (Pubitemid 28215599)
43. Zhuge Y, Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell invasion across collagen barrier. J Biol Chem 2001;276:16248-56.